基因标志物作为口腔癌患者预后和治疗反应的预测指标：一项前瞻性研究。
Genetic Markers as Predictors of Prognosis and Treatment Response in Patients with Oral Cancer: A Prospective Study.
作者信息
Mohammed P Rishal, Dash Mitali, Pati Seema, Yaqoob Ashfaq, Sanda Sailaja, Nelson Anish, Tiwari Heena D
机构信息
College of Dental Medicine, Qatar University, Doha, Qatar.
Department of Pathology, S. C. B. Medical College, Cuttack, Odisha, India.
出版信息
J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S439-S441. doi: 10.4103/jpbs.jpbs_1447_24. Epub 2025 Feb 25.
INTRODUCTION
"Oral squamous cell carcinoma (OSCC)" is a prevalent malignancy globally, with significant morbidity and mortality. Genetic markers are emerging as vital tools in predicting prognosis and treatment responses. This research explores genetic markers' role in OSCC prognosis and therapeutic outcomes.
METHODS
This prospective research analyzed 150 OSCC patients, investigating the prognostic value of three genetic markers: TP53 mutations, miR-31 expression, and "mismatch repair (MMR)" protein loss.
RESULTS
Patients with TP53 mutations exhibited lower survival rates ( < 0.05). Elevated miR-31 was associated with aggressive disease ( < 0.01), while MMR loss correlated with advanced tumor stages ( < 0.001).
CONCLUSION
Genetic markers, like TP53 mutations, miR-31, and MMR loss, can effectively predict prognosis and treatment responses in OSCC. Integrating these markers into clinical practice can enhance personalized treatment strategies.
引言
“口腔鳞状细胞癌（OSCC）”是全球一种常见的恶性肿瘤，具有较高的发病率和死亡率。基因标志物正成为预测预后和治疗反应的重要工具。本研究探讨基因标志物在OSCC预后和治疗结果中的作用。
方法
这项前瞻性研究分析了150例OSCC患者，研究了三种基因标志物的预后价值：TP53突变、miR-31表达和“错配修复（MMR）”蛋白缺失。
结果
TP53突变患者的生存率较低（<0.05）。miR-31升高与侵袭性疾病相关（<0.01），而MMR缺失与肿瘤晚期相关（<0.001）。
结论
TP53突变、miR-31和MMR缺失等基因标志物可有效预测OSCC的预后和治疗反应。将这些标志物整合到临床实践中可增强个性化治疗策略。
Zotero 插件